News

Doping for UK's biomedicine
Enlarge image

BusinessUK

Doping for UK's biomedicine

03.08.2012 - The UK government has pledged to invest additional €49m (£39m) in the country's life science research.

The Biomedical Catalyst Fund commited €12,6m (£10m) to 14 universities and 18 small- and medium-sized enterprises (SMEs) to explore the market potential of early-stage ideas. Each of the universities received up to £750k, while each company received up to £150k to propel their projects. These are the first investments for the three-year, €227m (£180m) fund. It is part of the Strategy for Life Science unveiled by UK’s Prime Minister David Cameron December last year to foster the domestic life science industry. The grants will fund about 150 pilot projects, allowing academic researchers to begin the process of turning a bright idea into a viable proposition. Universities have control over allocating the funding internally, allowing them to respond rapidly to new opportunities and have the flexibility to pursue the most promising translational research opportunities.

In an effort to establish four e-health centres of excellence in London, Manchester, Dundee and Swansea, UK’s Medical Research Council has teamed up with a consortium of ten public and charity research funders. The centres will focus on conditions including cancer, diabetes, obesity and cardiovascular disease. The researchers working at these centers will link information in NHS health records with other forms of research and routinely-collected data to improve patient care and public health.

Only days ago, Cameron unveiled plans to converse the Olympic drug testing laboratories located in Harlow into a phenome research centre after the Games are complete. The concept of the phenome encapsulates all of an individual’s traits, which are the outcome of a continuous interplay between their genes and the environment. It will be funded by €12,6m (£10m) investments over five years by both the Medical Research Council and the Department of Health’s National Institute for Health Research. Two companies who make scientific instruments - Bruker, and Waters Corporation – will invest additional €25,2m (£20m). Imperial College and King’s College London will be academic partners in the project.

http://www.european-biotechnology-news.com/news/news/2012-03/doping-for-uks-biomedicine.html

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX2.48 EUR3.77%
  • 4SC1.12 EUR2.75%
  • VITA 344.00 EUR2.04%

FLOP

  • ADDEX2.99 CHF-7.14%
  • BIOFRONTERA2.18 EUR-5.22%
  • SARTORIUS94.26 EUR-3.32%

TOP

  • SANTHERA92.00 CHF35.4%
  • PAION2.98 EUR23.1%
  • CO.DON3.02 EUR20.8%

FLOP

  • ADDEX2.99 CHF-25.8%
  • EVOTEC3.00 EUR-19.4%
  • MEDIGENE4.03 EUR-13.3%

TOP

  • SANTHERA92.00 CHF2188.6%
  • CO.DON3.02 EUR235.6%
  • PAION2.98 EUR186.5%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.23 EUR-41.0%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014